The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as ... which is also known as non-alcoholic steatohepatitis (NASH). The results come from Part 1 of the ESSENCE trial, which ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Less than five years on from when Novo Nordisk's semaglutide drug received FDA approval for weight loss (Wegovy), the Danish pharmaceutical company has announced it will seek regulatory approval ...

As a pioneer in diabetes care, Novo Nordisk NVO claims ... diabetes market share. Semaglutide is also being studied in areas including liver disease (NASH) and Alzheimer’s, and Novo could ...

Based on SOUL findings, Novo Nordisk submitted a label extension ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound ...

executive vice president for Development at Novo Nordisk. "These data, alongside our other data being presented at ACC, reinforce the comprehensive set of health benefits of semaglutide ...